A hard look at angiotensin receptor blockers in heart failure

Journal of the American College of Cardiology

Volumn 44, Issue 9, 2004, Pages 1841-1846

  Gring, Christian N ^a   Francis, Gary S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; LISINOPRIL; LOSARTAN; PLACEBO; SODIUM; VALSARTAN;

ACUTE HEART FAILURE; ALDOSTERONE RELEASE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR PERFORMANCE; CELL PROLIFERATION; CLINICAL TRIAL; DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG POTENCY; HEART LEFT VENTRICLE FAILURE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MONOTHERAPY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM ABSORPTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEALTH PLANNING GUIDELINES; HEART FAILURE, CONGESTIVE; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 7044269274     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.07.044     Document Type: Review

References (24)

1. M.D. Flather, S. Yusuf, L Køber Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients Lancet 355 2000 1575 1581
2. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
3. K. Swedberg, J. Kjekshus, S. Snapinn for the CONSENSUS Investigators Long term survival in severe heart failure in patients treated with enalapril: ten year follow-up of CONSENSUS I Eur Heart J 20 1999 136 139
4. M.C. Petrie, N. Padmanabhan, J.E. McDonald, C. Hillier, J.M.C. Connell, J.J.V. McMurray Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease J Am Coll Cardiol 37 2001 1056 1061
5. H. Urata, B. Healy, R.W. Stewart, M. Bumpus, A. Husain Angiotensin II-forming pathways in normal and failing human hearts Circ Res 66 1990 883 890
6. E. Roig, F. Perez-Villa, M Morales Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure Eur Heart J 21 2000 53 57
7. M. Burnier, H.R. Brunner Angiotensin II receptor antagonists Lancet 355 2000 637 645
8. T. Unger The role of the renin-angiotensin system in the development of cardiovascular disease Am J Cardiol 89 Suppl 2002 3A 10A
9. A.D. Struthers Aldosterone escape during ACE inhibitor therapy in chronic heart failure Eur Heart J 16 Suppl N 1995 103 106
10. W.H.W. Tang, R.H. Vagelos, Y Yee Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure J Am Coll Cardiol 39 2002 70 78
11. R.J. MacFadyen, A.F.C. Lee, J.J. Morton, S.D. Pringle, A.D. Struthers How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 82 1999 57 61
12. 1 receptor: gain of function study using gene transfer Proc Natl Acad Sci 92 1995 10663 10667
13. J.J. McMurray, J. Odie;stergren, K Swedberg Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 2003 767 771
14. J.N. Cohn, G. Tognoni for the Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675
15. C.B. Granger, J.J.V. McMurray, S Yusuf Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet 362 2003 772 776
16. B. Pitt, P.A. Poole-Wilson, R Segal Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival study (ELITE II) Lancet 355 2000 1582 1587
17. K. Dickstein, J. Kjekshus Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial Lancet 360 2002 752 760
18. M.A. Pfeffer, J.J. McMurray, E.J Velazquez Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 2003 1893 1906
19. M. Packer, P.A. Poole-Wilson, P.W Armstrong Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure Circulation 100 1999 2312 2318
20. A.T. Hirsch, C.E. Talsness, H. Schunkert, M. Paul, V.J. Dzau Tissue-specific activation of cardiac angiotensin converting enzymes in experimental heart failure Circ Res 69 1991 475 482
21. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack trial JAMA 23 2002 981 997
22. The Prospective Studies Collaboration Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 2002 1903 1913
23. A.P. Maggioni, I. Anand, S.O. Gottlieb, R. Latini, G. Tognoni, J.N. Cohn Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors J Am Coll Cardiol 40 2002 1414 1421
24. Available at: http://www.drugstore.com/pharmacy/drugindex/. Accessed May 2004.